(Q44969922)

English

The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity

scientific article published in January 1988

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

chronic leukemia

1 reference

based on heuristic

inferred from title

author name string

J Shima

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

T Yoshioka

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

H Nakajima

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

H Fujiwara

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

T Hamaoka

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

publication date

1 January 1988

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

43-47

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Adjuvant activity of N-acetyl muramyl dipeptides for the induction of delayed-type hypersensitivity to azobenzenearsonate-N-acetyl-L-tyrosine in guinea pigs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of tumor cell rejection in the low responsive YAC-lymphoma strain A host combination by immunization with somatic cell hybrids

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of structure and adjuvant activity of N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP), its derivatives and analogues. Anti-adjuvant and competition properties of stereoisomers

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spontaneous murine B-cell leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. III. Amplification of a generation of tumor-specific killer T-lymphocyte activities by suppressor T-cell-depleted hapten-reactive T lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant activity of synthetic N-acetylmuramyl-l-alanyl-d-isoglutamine and related compounds on cell-mediated cytotoxicity in syngeneic mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The augmentation of tumor-specific immunity by virus help. I. Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specific adoptive immunotherapy with tumor-specific cytotoxic T-lymphocyte clone for murine malignant gliomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of immune responsiveness in a genetically low-responsive tumor-host combination by chemical modification of the immunogen

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunologic approach to cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The augmentation of in vitro and in vivo tumor-specific T cell-mediated immunity by amplifier T lymphocytes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced immunogenicity of chemically-coated syngeneic tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunobiology of a Spontaneous Murine B Cell Leukemia (BCL1)

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids

1 reference

https://pubmed.ncbi.nlm.nih.gov/2964268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00199846

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44969922&oldid=2207017825"